Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$13.01 USD

13.01
13,877,863

-1.39 (-9.65%)

Updated May 17, 2024 04:00 PM ET

After-Market: $13.01 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

2 items in cart

View Cart/Checkout

Novavax, Inc. [NVAX]

Reports for Purchase

Showing records 241 - 260 ( 294 total )

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 241

09/19/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 22

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 242

09/19/2014

Industry Report

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 243

09/18/2014

Company Report

Pages: 11

Assuming Coverage with an OUTPERFORM and $10 PT

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 244

05/08/2014

Company Report

Pages: 5

Q1:14 Financial Results

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 245

05/04/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE: The Week Ahead in Life Sciences - Upcoming Events for the Week of May 5

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 246

04/30/2014

Daily Note

Pages: 6

Experimental Vaccines Elicit Immune Responses Against Coronavirus in Mice

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 247

04/30/2014

Daily Note

Pages: 6

Experimental Vaccines Elicit Immune Responses Against Coronavirus in Mice

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 248

04/28/2014

Daily Note

Pages: 4

Positive Top-line Results from RSV-F Phase 2 Trial

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 249

04/28/2014

Daily Note

Pages: 4

Positive Top-line Results from RSV-F Phase 2 Trial

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 250

03/16/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MARAI C

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 251

03/11/2014

Company Report

Pages: 7

Q4:13 Update; NVAX Initiated a Phase 1/2 Study of H7N9 Avian Influenza VLP Vaccine Candidate

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 252

03/10/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 10

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 253

12/16/2013

Company Report

Pages: 6

Updating Model for RSV and Raising Price Target to $12/Share from $4/Share - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 254

11/11/2013

Company Report

Pages: 6

Q3:13 Earnings Reported, RSV-F Trial Enrolled and BARDA Influenza Trials Initiated - Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 255

09/25/2013

Daily Note

Pages: 5

Analyst Update Call and Financing

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 256

09/12/2013

Daily Note

Pages: 4

Phase I RSV-F Vaccine Data Presented at ICAAC

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 257

09/06/2013

Daily Note

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 258

08/15/2013

Daily Note

Pages: 4

Phase I/II vaccine that uses Novavax''s Isconova adjuvant the subject of a Late Breaker at the upcoming ICAAC conference, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 259

08/09/2013

Company Report

Pages: 6

Q2:13 EPS, Broad Vaccine Platform Continues to Progress, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Novavax, Inc.

Industry: Medical - Biomedical and Genetics

Record: 260

07/15/2013

Daily Note

Pages: 5

Research coverage are Under Review pending reassignment to a new analyst.

Provider: BRINSON PATRICK SECURITIES CORPORATION

Price: 10.00

Research Provided by a Third Party